Risk of infection lower with SGLT2i than DPP4i

被引：0
|
作者：
机构：
来源：
Reactions Weekly | 2024年 / 2017卷 / 1期
关键词：
D O I：
10.1007/s40278-024-62986-3
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：10 / 10
相关论文
共 50 条
  • [1] Patients' Preference Between DPP4i and SGLT2i for Type 2 Diabetes Treatment: A Cross-Sectional
    Costa Gil, Jose Esteban
    Garnica Cuellar, Juan Carlos
    Perez Terns, Paula
    Ferreira-Hermosillo, Aldo
    Cetina Canto, Jose Antonio
    Garduno Perez, Angel Alfonso
    Mendoza Martinez, Pedro
    Rista, Lucas
    Sosa-Caballero, Alejandro
    Vazquez-Mendez, Estefania
    Tejado Gallegos, Luis Fernando
    Chen, Hungta
    Elizalde, Agustina
    Tomatis, Virginia B.
    PATIENT PREFERENCE AND ADHERENCE, 2022, 16 : 1201 - 1211
  • [2] The Association of SGLT2i vs. DPP4i on Fracture-Cohort Study of Veterans with Diabetes
    Snyder, Kathryn D.
    Hackstadt, Amber J.
    Griffin, Katherine E.
    Horton, Thomas G.
    Javid, Amir Hossein
    Hung, Adriana M.
    Greevy, Robert A., Jr.
    Roumie, Christianne
    DIABETES, 2024, 73
  • [3] Use of DPP4i/SGLT2i Fixed Dose Combinations in Indian Clinical Practice-A KAP Survey
    Saboo, Bharat
    Prajapati, Charmy M.
    Shetty, Parvan A.
    Muralidharan, Parthasarathy
    Qamra, Amit
    DIABETES, 2024, 73
  • [4] COMPARATIVE EFFECTIVENESS OF SGLT2I VERSUS DPP4I ON CARDIOVASCULAR AND RENAL OUTCOMES IN ROUTINE-CARE SETTINGS
    Fu, Edouard
    Trevisan, Marco
    Lanka, Vivekananda
    Clase, Catherine M.
    Xu, Yang
    Dekker, Friedo W.
    Van Diepen, Merel
    Carrero, Juan Jesus
    NEPHROLOGY DIALYSIS TRANSPLANTATION, 2021, 36
  • [5] Lower risks of incident colorectal cancer in SGLT2i users compared to DPP4i users: A propensity score-matched study with competing risk analysis
    Chan, Raymond Ngai Chiu
    Chan, Robert Ngai Fung
    Chou, Oscar Hou In
    Tse, Gary
    Lee, Sharen
    EUROPEAN JOURNAL OF INTERNAL MEDICINE, 2023, 110 : 125 - 127
  • [6] Is SGLT2i superior to DPP4i for primary and secondary prevention of cardiovascular diseases and death in patients with type 2 diabetes?
    Zhao, Li-Min
    Huang, Jia-Nan
    Qiu, Mei
    Chang, Rong
    PHARMACOLOGICAL RESEARCH, 2021, 174
  • [7] Study of efficacy and safety of SGLT2i in comparison with DPP4i in T2DM subjects inadequately controlled on Metformin
    Pattanaik, S. R.
    Sinha, A. Kumar
    Kumar, S.
    Chandra, A.
    DIABETES RESEARCH AND CLINICAL PRACTICE, 2022, 186
  • [8] Expert Opinion: Optimum Clinical Approach to Combination-Use of SGLT2i + DPP4i in the Indian Diabetes Setting
    Manoj Chadha
    Ashok Kumar Das
    Prasun Deb
    Kalyan Kumar Gangopadhyay
    Shashank Joshi
    Jothydev Kesavadev
    Rajiv Kovil
    Surender Kumar
    Anoop Misra
    Viswanathan Mohan
    Diabetes Therapy, 2022, 13 : 1097 - 1114
  • [9] Factors associated with DPP4i or SGLT2i utilisation: a retrospective cohort study among people with type 2 diabetes mellitus
    Sim, Ruth
    Chong, Chun Wie
    Loganadan, Navin Kumar
    Adam, Noor Lita
    Hussein, Zanariah
    Lee, Shaun Wen Huey
    JOURNAL OF PHARMACY PRACTICE AND RESEARCH, 2024,
  • [10] Response to the comment "Is SGLT2i superior to DPP4i for primary and secondary prevention of cardiovascular diseases and death in patients with type 2 diabetes?"
    Mascolo, Annamaria
    Scavone, Cristina
    Scisciola, Lucia
    Chiodini, Paolo
    Capuano, Annalisa
    Paolisso, Giuseppe
    PHARMACOLOGICAL RESEARCH, 2021, 174
12345